| Custom ID | DOI | AUTHOR | DATASET |
| 888800000002 | 10.1101/2020.03.29.20041962 | Gao T (2020) | Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation |
| 888800000003 | 10.1101/2020.02.16.951723 | Sun C (2020) | SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development |
| 888800000005 | 10.1101/2020.03.14.988345 | Wang K (2020) | SARS-CoV-2 invades host cells via a novel route: CD147-spike protein |
| 888800000006 | 10.1101/2020.02.17.951848 | Zhou Q (2020) | Structure of dimeric full-length human ACE2 in complex with B0AT1 |
| 888800000007 | 10.1101/2020.02.26.964882 | Jin Z (2020) | Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION] |
| 888800000008 | 10.1101/2020.03.29.013490 | Wang C (2020) | Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2 |
| 888800000009 | 10.1101/2020.03.25.996348 | Dai W (2020) | Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease |
| 888800000010 | 10.1101/2020.03.15.992883 | Joyce MG (2020) | A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein |
| 888800000011 | 10.1101/2020.03.16.993386 | Gao Y (2020) | Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target |
| 888800000013 | 10.1101/2020.04.15.042085 | Bestle D (2020) | TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets |
| 888800000018 | 10.1101/2020.04.19.049643 | Zeng X (2020) | Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy |
| 888800000020 | 10.1101/2020.04.22.046565 | Liu Y (2020) | Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2 |
| 888800000021 | 10.1101/2020.04.21.053017 | Walker A (2020) | Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases |
| 888800000022 | 10.1101/2020.04.17.047498 | Rosas Lemus M (2020) | The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine |
| 888800000025 | 10.1101/2020.04.29.068890 | Rut W (2020) | Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design |
| 888800000029 | 10.1101/2020.05.02.20086876 | Zhang D (2020) | Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS) |
| 888800000031 | 10.1101/2020.05.06.079830 | Zha L (2020) | Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles |
| 888800000032 | 10.1101/2020.05.02.043554 | Gunther S (2020) | Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease |
| 888800000034 | 10.1101/2020.05.03.074914 | Liu X (2020) | Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection |
| 888800000035 | 10.1101/2020.05.21.109157 | Lui I (2020) | Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity |
| 888800000036 | 10.1101/2020.05.21.107870 | Partridge LJ (2020) | Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line |
| 888800000037 | 10.1101/2020.05.13.092478 | Chiodo F (2020) | Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota |
| 888800000038 | 10.1101/2020.05.12.091298 | Seydoux E (2020) | Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual |
| 888800000040 | 10.1101/2020.05.12.092171 | Zhou X (2020) | Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation |
| 888800000041 | 10.1101/2020.06.17.156455 | Stukalov A (2020) | Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV |
| 888800000042 | 10.1101/2020.06.05.135921 | Bertoglio F (2020) | SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface |
| 888800000043 | 10.1101/2020.06.05.135699 | Moustaqil M (2020) | SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts. |
| 888800000046 | 10.1101/2020.06.17.158121 | Cubuk J (2020) | The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA |
| 888800000050 | 10.1101/2020.06.07.138677 | Luan X (2020) | Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376 |
| 888800000052 | 10.1101/2020.06.06.137513 | Lou Y (2020) | Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries |
| 888800000054 | 10.1101/2020.06.16.155812 | Li J (2020) | Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin |
| 888800000056 | 10.1101/2020.06.16.154708 | Hanson QM (2020) | Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay |
| 888800000063 | 10.1101/2020.07.31.230730 | Cao W (2020) | Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction |
| 888800000064 | 10.1101/2020.07.24.219857 | Esparza TJ (2020) | High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme |
| 888800000065 | 10.1101/2020.07.25.221036 | Shilts J (2020) | No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor |
| 888800000066 | 10.1101/2020.07.13.201517 | Davies JP (2020) | Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies |
| 888800000067 | 10.1101/2020.07.31.229781 | Alitongbieke G (2020) | Study on beta-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2 |
| 888800000069 | 10.1101/2020.07.27.224089 | Beasley MD (2020) | Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries |
| 888800000070 | 10.1101/2020.07.29.227462 | Gao C (2020) | SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors |
| 888800000071 | 10.1101/2020.07.26.222026 | Zheng Y (2020) | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling |
| 888800000072 | 10.1101/2020.07.30.229187 | Shi W (2020) | A dynamic regulatory interface on SARS-CoV-2 RNA polymerase |
| 888800000075 | 10.1101/2020.07.15.204404 | Schmidt N (2020) | A direct RNA-protein interaction atlas of the SARS-CoV-2 RNA in infected human cells |
| 888800000076 | 10.1101/2020.08.03.234914 | Cao L (2020) | De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. [DEPRECATED] |
| 888800000078 | 10.1101/2020.07.17.208959 | Fu Z (2020) | Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules |
| 888800000079 | 10.1101/2020.07.31.231282 | Tee KL (2020) | Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay |
| 888800000080 | 10.1101/2020.07.25.220806 | Temerozo JR (2020) | The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells. |
| 888800000081 | 10.1101/2020.08.03.234559 | Addetia A (2020) | SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98 |
| 888800000082 | 10.1101/2020.08.28.272955 | Laurent E (2020) | Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms |
| 888800000083 | 10.1101/2020.08.20.259770 | Lapointe CP (2020) | Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation |
| 888800000084 | 10.1101/2020.08.16.252973 | Han L (2020) | SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways |
| 888800000085 | 10.1101/2020.08.06.238915 | Watson A (2020) | Peptide Antidotes to SARS-CoV-2 (COVID-19) |
| 888800000086 | 10.1101/2020.08.12.247767 | Yang Z (2020) | Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2 |
| 888800000087 | 10.1101/2020.08.12.246389 | Risner K (2020) | Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture |
| 888800000088 | 10.1101/2020.08.08.238469 | Schoof M (2020) | An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation |
| 888800000089 | 10.1101/2020.08.14.250258 | Chen Y (2020) | Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro |
| 888800000090 | 10.1101/2020.08.09.242917 | Thepaut M (2020) | DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist |
| 888800000093 | 10.1101/2020.08.18.256776 | Andres AD (2020) | SARS-CoV-2 ORF9c Is a Membrane-Associated Protein that Suppresses Antiviral Responses in Cells |
| 888800000094 | 10.1101/2020.08.13.249177 | Carrique L (2020) | The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer |
| 888800000095 | 10.1101/2020.08.13.248211 | Baddock HT (2020) | Characterisation of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification |
| 888800000096 | 10.1101/2020.08.10.244525 | Malla TN (2020) | Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals |
| 888800000097 | 10.1101/2020.08.11.244863 | Pillon MC (2020) | Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15 |
| 888800000098 | 10.1101/2020.08.12.247338 | Wang C (2020) | Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection |
| 888800000099 | 10.1101/2020.08.14.251421 | Wilamowski M (2020) | Methylation of RNA Cap in SARS-CoV-2 captured by serial crystallography |
| 888800000100 | 10.1101/2020.08.13.248872 | Wei C (2020) | SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry |
| 888800000101 | 10.1101/2020.08.14.251207 | Heaton BE (2020) | SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2 |
| 888800000103 | 10.1101/2020.08.09.242867 | Gai J (2020) | A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential |
| 888800000104 | 10.1101/2020.09.03.282103 | Samavarchi-Tehrani P (2020) | A SARS-CoV-2 - host proximity interactome |
| 888800000105 | 10.1101/2020.09.09.287508 | Gu Y (2020) | Interaction network of SARS-CoV-2 with host receptome through spike protein |
| 888800000106 | 10.1101/2020.08.29.273441 | Bojadzic D (2020) | Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19 |
| 888800000107 | 10.1101/2020.09.04.282558 | Bouwman KM (2020) | Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins |
| 888800000108 | 10.1101/2020.08.28.271601 | Dash P (2020) | Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutated receptor binding domain with ACE2 receptor |
| 888800000109 | 10.1101/2020.08.28.269175 | St-Germain JR (2020) | A SARS-CoV-2 BioID-based virus-host membrane protein interactome and virus peptide compendium: new proteomics resources for COVID-19 research |
| 888800000111 | 10.1101/2020.09.04.280081 | Qiang X (2020) | Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction. |
| 888800000112 | 10.1101/2020.09.09.287987 | Durdagi S (2020) | Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations of SARS-CoV-2 Main Protease Active Site for Improved Drug Repurposing |
| 888800000113 | 10.1101/2020.09.01.277954 | Bartolome A (2020) | Angiotensin converting enzyme 2 is a novel target of the secretase complex |
| 888800000115 | 10.1101/2020.09.09.289488 | Kotani N (2020) | Candidate screening of host cell membrane proteins involved in SARS-CoV-2 entry |
| 888800000116 | 10.1101/2020.08.27.270637 | Flower TG (2020) | Structure of SARS-CoV-2 ORF8, a rapidly evolving coronavirus protein implicated in immune evasion |
| 888800000117 | 10.1101/2020.09.21.307439 | Wang X (2020) | Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution |
| 888800000118 | 10.1101/2020.09.14.295956 | Lin C (2020) | Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction |
| 888800000119 | 10.1101/2020.09.16.297366 | Sagar S (2020) | Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells |
| 888800000120 | 10.1101/2020.09.18.301952 | Xiao T (2020) | A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro |
| 888800000121 | 10.1101/2020.09.16.297945 | Meyer B (2020) | Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing |
| 888800000122 | 10.1101/2020.09.22.308338 | Wagner TR (2020) | NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response |
| 888800000123 | 10.1101/2020.09.20.297242 | Ren W (2020) | Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry |
| 888800000124 | 10.1101/2020.09.13.295691 | Olaleye OA (2020) | Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2. |
| 888800000125 | 10.1101/2020.09.16.300319 | Tada T (2020) | A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture |
| 888800000126 | 10.1101/2020.09.16.299891 | Higuchi Y (2020) | High affinity modified ACE2 receptors prevent SARS-CoV-2 infection |
| 888800000127 | 10.1101/2020.09.16.20190694 | Ichimura T (2020) | KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney |
| 888800000128 | 10.1101/2020.11.04.361154 | de Vries (2020) | Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets |
| 888800000129 | 10.1101/2020.10.13.336800 | Yan R (2020) | Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies |
| 888800000130 | 10.1101/2020.09.27.315796 | Bauer MS (2020) | A Tethered Ligand Assay to Probe the SARS-CoV-2 ACE2 Interaction under Constant Force |
| 888800000131 | 10.1101/2020.10.06.328112 | Lutomski CA (2020) | Autoproteolytic Products of the SARS-CoV-2 Nucleocapsid Protein are Primed for Antibody Evasion and Virus Proliferation |
| 888800000132 | 10.1101/2020.10.31.363473 | Stevens BR (2020) | TMPRSS2 and ADAM17 interactions with ACE2 complexed with SARS-CoV-2 and B0AT1 putatively in intestine, cardiomyocytes, and kidney |
| 888800000133 | 10.1101/2020.10.23.350348 | Tang X (2020) | Transferrin receptor is another receptor for SARS-CoV-2 entry |
| 888800000134 | 10.1101/2020.11.04.361576 | Li W (2020) | Human Identical Sequences of SARS-CoV-2 Promote Clinical Progression of COVID-19 by Upregulating Hyaluronan via NamiRNA-Enhancer Network |
| 888800000135 | 10.1101/2020.10.29.352450 | Bakovic A (2020) | Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 |
| 888800000136 | 10.1101/2020.10.26.356048 | Liu G (2020) | ISG15-dependent Activation of the RNA Sensor MDA5 and its Antagonism by the SARS-CoV-2 papain-like protease |
| 888800000137 | 10.1101/2020.10.16.342097 | Gao X (2020) | Duple extinguishment of COVID-19: single compound synergized inhibition of SARS-CoV-2 replication and direct suppression of inflammatory cytokines in vitro/vivo |
| 888800000138 | 10.1101/2020.10.13.337584 | Roy A (2020) | ACIS, A Novel KepTide(tm), Binds to ACE-2 Receptor and Inhibits the Infection of SARS-CoV2 Virus in vitro in Primate Kidney Cells: Therapeutic Implications for COVID-19 |
| 888800000139 | 10.1101/2020.10.30.361873 | Andring JT (2020) | Amino acid transporter B0AT1 influence on ADAM17 interactions with SARS-CoV-2 receptor ACE2 putatively expressed in intestine, kidney, and cardiomyocytes |
| 888800000140 | 10.1101/2020.10.23.347534 | Mellott D (2020) | A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells |
| 888800000141 | 10.1101/2020.10.06.327742 | Kliche J (2020) | Cytoplasmic short linear motifs in ACE2 and integrin beta3 link SARS-CoV-2 host cell receptors to endocytosis and autophagy |
| 888800000142 | 10.1101/2020.10.18.344622 | Chan KK (2020) | An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants |
| 888800000143 | 10.1101/2020.11.01.363788 | Sun J (2020) | Discovery of five HIV nucleoside analog reverse-transcriptase inhibitors (NRTIs) as potent inhibitors against the RNA-dependent RNA polymerase (RdRp) of SARS-CoV and 2019-nCoV |
| 888800000144 | 10.1101/2020.10.30.362335 | Hu Y (2020) | Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture |
| 888800000145 | 10.1101/2020.10.11.335299 | Gobeil S (2020) | D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction |
| 888800000146 | 10.1101/2020.10.06.327445 | Flynn RA (2020) | Systematic discovery and functional interrogation of SARS-CoV-2 viral RNA-host protein interactions during infection |
| 888800000147 | 10.1101/2020.09.24.312553 | Li Y (2020) | SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes |
| 888800000148 | 10.1101/2020.10.22.351569 | Nguyen HT (2020) | Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects |
| 888800000149 | 10.1101/2020.10.22.351056 | Bojadzic D (2020) | Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2 |
| 888800000150 | 10.1101/2020.10.08.20209114 | Wu F (2020) | Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis |
| 888800000151 | 10.1101/2020.09.30.317818 | Hsu AC-Y (2020) | SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro |
| 888800000152 | 10.1101/2020.11.05.369264 | Soh WT (2020) | The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN |
| 888800000153 | 10.1101/2020.12.02.408153 | Roth A (2020) | LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro |
| 888800000154 | 10.1101/2020.11.24.20237628 | Al Ahmad M (2020) | Development of an Optical Assay to Detect SARS-CoV-2 Spike Protein Binding Interactions with ACE2 and Disruption of these Interactions Using Electric Current |
| 888800000155 | 10.1101/2020.12.06.413443 | Svilenov HL (2020) | Efficient inhibition of SARS-CoV-2 strains by a novel ACE2-IgG4-Fc fusion protein with a stabilized hinge region |
| 888800000156 | 10.1101/2020.12.01.406116 | Tito A (2020) | A pomegranate peel extract as inhibitor of SARS-CoV-2 Spike binding to human ACE2 (in vitro): a promising source of novel antiviral drugs |
| 888800000157 | 10.1101/2020.11.24.393629 | Wang X (2020) | Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2 |
| 888800000158 | 10.1101/2020.12.03.409441 | Rossetti GG (2020) | Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico screens |
| 888800000159 | 10.1101/2020.11.11.378018 | Eberle RJ (2020) | The repurposed drugs suramin and quinacrine inhibit cooperatively in vitro SARS-CoV-2 3CLpro |
| 888800000160 | 10.1101/2020.11.12.378422 | Guenther S (2020) | Inhibition of SARS-CoV-2 main protease by allosteric drug-binding |
| 888800000161 | 10.1101/2020.12.06.412759 | Calistri A (2020) | The new generation hDHODH inhibitor MEDS433 hinders the in vitro replication of SARS-CoV-2 |
| 888800000162 | 10.1101/2020.12.03.409318 | Bertoglio F (2020) | A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations |
| 888800000163 | 10.1101/2020.11.06.368191 | Kraus A (2020) | A zebrafish model for COVID-19 recapitulates olfactory and cardiovascular pathophysiologies caused by SARS-CoV-2 |
| 888800000164 | 10.1101/2020.12.23.424149 | Noske G (2020) | A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process |
| 888800000165 | 10.1101/2020.12.18.423427 | Zhao Y (2020) | SARS-CoV-2 spike protein interacts with and activates TLR4 |
| 888800000166 | 10.1101/2020.12.19.423537 | Kitamura N (2020) | An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity |
| 888800000167 | 10.1101/2020.12.23.424171 | Schmitz A (2020) | A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism |
| 888800000168 | 10.1101/2020.12.31.424961 | Chen Z (2021) | Comprehensive analysis of the host-virus interactome of SARS-CoV-2 |
| 888800000169 | 10.1101/2020.12.21.423721 | Avolio E (2020) | The SARS-CoV-2 spike protein disrupts the cooperative function of human cardiac pericytes - endothelial cells through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease |
| 888800000170 | 10.1101/2020.12.19.423584 | Garcia-Dorival I (2020) | Identification of NPC1 as a novel SARS-CoV-2 intracellular target |
| 888800000171 | 10.1101/2020.12.26.424423 | Durdagi S (2020) | The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies |
| 888800000172 | 10.1101/2020.12.18.423415 | Madan T (2020) | A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples |
| 888800000173 | 10.1101/2020.12.29.424698 | Yang X (2020) | An Ultrasensitive Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and in vitro |
| 888800000174 | 10.1101/2020.12.20.422820 | Fiedler S (2020) | In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum |
| 888800000175 | 10.1101/2020.12.22.422708 | Shepley-McTaggart A (2020) | SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1 |
| 888800000176 | 10.1101/2020.12.18.423418 | Hsieh M-H (2020) | Human Surfactant Protein D Binds S1 and Receptor Binding Domain of Spike protein and acts as an entry inhibitor of SARS-CoV-2 Pseudotyped viral particles in vitro |
| 888800000177 | 10.1101/2020.12.16.422677 | Kuzikov M (2020) | Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen |
| 888800000178 | 10.1101/2020.12.30.424801 | Woo HG (2020) | Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro |
| 888800000179 | 10.1101/2020.12.26.424422 | Xu W (2020) | Extensive High-Order Complexes within SARS-CoV-2 Proteome Revealed by Compartmentalization-Aided Interaction Screening |
| 888800000180 | 10.1101/2020.12.09.417741 | Armstrong L (2020) | Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies |
| 888800000181 | 10.1101/2020.12.29.424682 | Kuznetsov A (2020) | ACE2 peptide fragment interacts with several sites on the SARS-CoV-2 spike protein S1 |
| 888800000182 | 10.1101/2021.01.21.427657 | Choi R (2021) | High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity. |
| 888800000183 | 10.1101/2021.01.12.426388 | Kneller DW (2021) | Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease |
| 888800000184 | 10.1101/2021.01.17.427000 | Wan Y (2021) | Comprehensive mapping of SARS-CoV-2 interactions in vivo reveals functional virus-host interactions |
| 888800000185 | 10.1101/2021.01.19.427194 | Tian R (2021) | BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2 |
| 888800000186 | 10.1101/2021.01.11.426269 | Zhu X (2021) | Cryo-EM Structure of the N501Y SARS-CoV-2 Spike Protein in Complex with a Potent Neutralizing Antibody |
| 888800000187 | 10.1101/2021.01.05.425478 | Kamle S (2021) | Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19 |
| 888800000188 | 10.1101/2021.01.14.426695 | Carnell GW (2021) | SARS-CoV-2 spike protein arrested in the closed state induces potent neutralizing responses |
| 888800000189 | 10.1101/2021.01.13.21249429 | Hultstrom M (2021) | Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients |
| 888800000190 | 10.1101/2021.01.19.427324 | Suryadevara N (2021) | Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein |
| 888800000191 | 10.1101/2021.01.11.426218 | Rapp M (2021) | Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class |
| 888800000192 | 10.1101/2021.01.07.425745 | Saramago M (2021) | New targets for drug design: Importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2 |
| 888800000193 | 10.1101/2021.01.12.426042 | Siniavin AE (2021) | Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor |
| 888800000194 | 10.1101/2021.01.07.425806 | Bell BN (2021) | Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library |
| 888800000195 | 10.1101/2021.01.20.427368 | Carlos AJ (2021) | GRP78 binds SARS-CoV-2 Spike protein and ACE2 and GRP78 depleting antibody blocks viral entry and infection in vitro |
| 888800000196 | 10.1101/2021.01.05.425516 | Verma R (2021) | RNA-protein interaction analysis of SARS-CoV-2 5'- and 3'-untranslated regions identifies an antiviral role of lysosome-associated membrane protein-2 |
| 888800000197 | 10.1101/2021.01.29.428890 | Berndt AJ (2021) | Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii |
| 888800000198 | 10.1101/2021.01.29.428834 | Bayarri-Olmos R (2021) | The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization |
| 888800000199 | 10.1101/2021.02.03.429601 | Prahlad J (2021) | Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain |
| 888800000200 | 10.1101/2021.02.03.429625 | Khalili Yazdi A (2021) | A high-throughput radioactivity-based assay for screening SARS-CoV-2 nsp10-nsp16 complex |
| 888800000201 | 10.1101/2021.02.01.429176 | Caillet-Saguy C (2021) | Host PDZ-containing proteins targeted by SARS-Cov-2 |
| 888800000202 | 10.1101/2021.02.11.430866 | Liu H (2021) | A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection |
| 888800000203 | 10.1101/2021.02.02.429311 | Ma H (2021) | Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain |
| 888800000204 | 10.1101/2021.02.19.424337 | Devkota K (2021) | Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors |
| 888800000205 | 10.1101/2021.02.13.431008 | Shen Z (2021) | Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures |
| 888800000206 | 10.1101/2021.02.17.431617 | Bollavaram K (2021) | Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to Proteolysis by Cathepsins B, K, L, S, and V |
| 888800000207 | 10.1101/2021.01.31.429023 | Minasov G (2021) | Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16 |
| 888800000208 | 10.1101/2021.02.03.429355 | Graham C (2021) | Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike |
| 888800000209 | 10.1101/2021.02.09.430451 | Spelios MG (2021) | A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding |
| 888800000210 | 10.1101/2021.02.02.428884 | Zhang G (2021) | The basis of a more contagious 501Y.V1 variant of SARS-COV-2 |
| 888800000211 | 10.1101/2021.02.16.431021 | Arutyunova E (2021) | N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 Mpro |
| 888800000212 | 10.1101/2021.02.07.429299 | Gu C (2021) | A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques |
| 888800000213 | 10.1101/2021.02.04.429751 | Slavin M (2021) | Targeted in situ cross-linking mass spectrometry and integrative modeling reveal the architectures of Nsp1, Nsp2, and Nucleocapsid proteins from SARS-CoV-2 |
| 888800000214 | 10.1101/2021.02.08.430344 | Zhao H (2021) | Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids |
| 888800000215 | 10.1101/2021.02.14.431117 | Tian F (2021) | Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2 |
| 888800000216 | 10.1101/2021.02.17.431755 | Zhao Y (2021) | SARS-CoV-2 nucleocapsid protein dually regulates innate immune responses |